Our Team

Heather Turner has served as Chief Executive Officer since January 2023. Heather brings over 20 years of leadership experience in life science companies including senior operational roles and legal expertise. Heather joined Carmot as Chief Operating Officer in 2022 and was responsible for Carmot’s operations and governance. In this role, Heather led the G&A functions as well as portfolio management. Prior to Carmot, Heather served as Chief General Counsel and Secretary at Lyell Immunopharma, Inc. serving as a member of the executive team and overseeing the legal organization. During her tenure she led and oversaw the finance, investor relations and alliance management functions. Notably, she oversaw the execution of the company’s $400 million Series C financing and the company’s IPO which raised gross proceeds of approximately $425 million, Nasdaq’s fourth largest biotech IPO. In addition, Heather significantly engaged in numerous strategic partnerships including the Company’s development and commercialization partnership with GSK which included a $200 million investment. Prior to Lyell, Heather served as Executive Vice President, General Counsel and Secretary of Sangamo Therapeutics, Inc. a publicly traded gene therapy and gene editing company, where she oversaw the legal and human resources organizations and led the company’s acquisition and integration of a publicly traded French company as well as its expansion into Europe. Prior to Sangamo, Heather served as Executive Vice President, General Counsel and Head of Portfolio Strategy at Atara Biotherapeutics, Inc., a publicly-traded allogeneic cell therapy company, where she oversaw legal, portfolio strategy, human resources and medical affairs. She also led secondary financings as well as international tax planning and implementation. Prior to Atara, Heather served as General Counsel and Secretary at Orexigen Therapeutics, Inc. a publicly-traded company focused on metabolic diseases. During her tenure at Orexigen, Heather oversaw the legal, human resources, government affairs and facilities functions. Heather was also actively involved in engagements with FDA and EMA related to their approvals of Orexigen’s obesity drug. Heather started her career at Cooley as a corporate securities associate. Heather received her J.D. from UCLA School of Law and her B.A. in Environmental Studies from the University of California, Santa Barbara.

Dr. Manu Chakravarthy leads research & development and oversees the execution of all clinical related activities. Prior to Carmot, Manu served as Executive Vice President and Chief Medical Officer at Axcella Health, Inc. overseeing all phases of clinical development, regulatory affairs, quality, and scientific communications. Prior to Axcella, Manu served as the Vice President and Global Head of External R&D and Innovation Strategy in Diabetes and Cardiovascular Research at Eli Lilly. Before his global leadership role at Lilly, Manu was a Distinguished Scientist at Merck and worked across the R&D spectrum from discovery, clinical pharmacology, biomarker development and late-stage drug development covering diverse disease areas. Dr. Chakravarthy received his MD from the University of Texas Houston Medical School and a PhD in Cell Biology & Physiology from the MD Anderson Cancer Center and University of Texas Graduate School of Biomedical Sciences combined MD-PhD program. He trained in Internal Medicine at the Hospital of the University of Pennsylvania, and in Endocrinology, Diabetes and Metabolism at Washington University School of Medicine in St. Louis. He is internationally recognized as a thought leader in metabolic diseases, reflected by his published work in numerous high-impact peer-reviewed scientific journals and invited speakership.

Michael Gray has served as Chief Operating Officer & Chief Financial Officer since June 2023. Mike brings nearly 20 years of public-private leadership experience including broad strategic, financial and operating experience in global life science companies. Prior to Carmot, Mike served as CFO and COO of Imara, Inc., a public biotech company where he was instrumental in transitioning the private company through its initial public offering (IPO) in 2020, and in building Imara from a virtual to operating company conducting Phase 2b global clinical trials in non-malignant hematology indications. Mike was also a leader on Imara’s strategic initiative which resulted in a successful asset sale and entry into a reverse merger transaction with Enliven Therapeutics. Prior to Imara, Mike held several C Suite posts at Arsanis, Inc., a global biotech company, working with the Board of Directors and leadership team to build its U.S. operations, complete a private financing and IPO, as well as its merger with X4 Pharmaceuticals. Mike previously held a variety of leadership positions at Curis, Inc., including CFO, CBO and COO, leading multiple equity and debt financings and business development transactions and overseeing various business and strategic initiatives. Previously, Mike held positions including Controller at Reprogenesis Inc., a biotechnology company focused on the development of cell therapy drug candidates, and as an audit professional for the accounting and consulting firm of Ernst & Young, LLP. Mike served on the board of directors of Therapeutics Acquisition Corporation, a special purpose acquisition corporation, from May 2020 to July 2021, when it completed its merger with POINT Biopharma.

Mike received his M.B.A. in corporate finance and entrepreneurial management from the F.W. Olin Graduate School of Business at Babson College and a B.S. in accounting from Bryant University.

David (Dave) Schubert joined Carmot Therapeutics with over 35 years of experience in regulatory, quality, drug development and process development. Most recently Dave was SVP Regulatory and Quality at Chiasma where he provided regulatory leadership and guidance to development, commercial, marketing, pharmacovigilance, corporate compliance and business development. Prior to Chiasma, Dave was VP Regulatory and Quality at Stealth Biotherapeutics Inc. a company developing novel and innovative mitochondrial targeted therapies for rare and common diseases. Dave has served as the regulatory and quality lead for several biotechs and his experience spans oral dosage forms, sterile injectables, cartridge/pen (combination products), and topicals (ophthalmic drops). In addition, Dave has wide-ranging GXP compliance experience supporting GLP, GCP, and GMP. Trained as a protein chemist, Dave started his career at the bench at Genetics Institute. It was here that he transitioned to large scale GMP process development, writing regulatory dossiers and supporting quality systems.

Heidi Brumbach joined Carmot in 2023 as Vice President of Human Resources bringing over 25 years of human resources knowledge to her role. Heidi is passionate about partnering with innovative leadership teams to create great places to work, where employees feel empowered and motivated to bring their best every day. She has experience in the professional services, technology and life sciences industries, including over 15 years at Confirmit, a Norwegian-headquartered software company, where she became the company’s first global HR leader with responsibility that grew to over 900 employees in 9 countries. She was most recently a Senior Consultant with Christine Mathews Consulting and enjoyed collaborating with her early-stage life sciences clients to develop and manage People infrastructure, programs and initiatives. Heidi holds senior human resources certifications including SPHR and SHRM-SCP.

Michael Elliott leads clinical operations. He has over two decades of experience in clinical trial management, spanning Phase 1 through pivotal Phase 3 trials, in over 20 countries. Michael has managed over 60 company-sponsored clinical trials and almost a dozen investigator-sponsored trails. Before joining Carmot, Michael was Senior Director, Clinical Development at NGM Biopharmaceuticals. In this role, he built and led the clinical operations group for NGM, which had multiple programs studying first-in-class, first-in-human product candidates. Previously, he was Director, Clinical Operations at Afferent Pharmaceuticals, a company which was acquired by Merck. Prior to Afferent, he was Director, Clinical Operations at Anthera Pharmaceuticals where he led the clinical operations department and supported the regulatory submission for a Special Protocol Assessment (SPA) with FDA. Michael earned a Bachelor of Arts from the University of Pittsburgh and Master of Arts from Xavier University.

Dr. Minako Pazdera joined Carmot in 2023 and oversees Carmot’s legal function. She brings over 20 years of experience working at a global large pharmaceutical company as well as smaller biotechnology companies. Previously, Minako was Vice President, Intellectual Property and Corporate Secretary at Lyell Immunopharma, Inc. Prior to Lyell, Minako was Vice President, Intellectual Property at Sangamo Therapeutics, Inc. Prior to Sangamo, Minako was at Genentech, Inc. where she held various positions including Associate General Counsel, Director of Patents-Oncology. Prior to going in-house, Minako practiced intellectual property law at Ropes & Gray, LLP and Fish & Neave, LLP in New York City and Marshall, Gerstein & Borun LLP in Chicago. Dr. Pazdera received her B.A in Molecular Cell Biology from the University of California, Berkeley, a Ph.D. in Biological Sciences from Carnegie Mellon University and a J.D. from Fordham University School of Law.

Dr. Rich Silva joined Carmot Therapeutics in April 2023 as the new Vice President of Chemistry, Manufacturing, and Controls (CMC). Rich’s 25-year career includes extensive experience in the commercialization of innovative therapies, as well as collaborations with leading global pharmaceutical companies.

Prior to joining Carmot Therapeutics, Rich held the position of Head of Technical Operations at Epizyme, where he managed pharmaceutical development, including drug substance synthesis, drug product formulation, and analytical method development. During his tenure, Rich led the post-launch development and manufacturing of Epizyme’s epigenetic therapy, Tazverik (tazemetostat), ensuring a robust commercial supply chain, compliance with Good Manufacturing Practices (GMP), and regulatory commitments, as well as technical oversight of drug substance (API) and drug product (DP) manufacturing processes. Additionally, Rich’s group advanced several candidates for first-in-human trials by providing phase-appropriate supply of drug substance and product, utilizing Quality by Design (QbD) principles.

Before his time at Epizyme, Rich served as Senior Director of Small Molecules Process Chemistry and Analytical at ImmunoGen, where he played a crucial role in the development and commercialization of ImmunoGen’s antibody-drug conjugate (ADC), ELAHERE (mirvetuximab soravtansine). In this capacity, he oversaw the optimization of synthetic routes, scale-up of process chemistry, and implementation of analytical methods to ensure product quality.

Rich’s career also includes positions of increasing responsibility at Genzyme, Vertex, and Bayer Chemicals, where he applied his expertise in organic chemistry, process development, and analytical techniques to advance various drug candidates. Dr. Silva earned his Ph.D. in Organic Chemistry from Dartmouth College.

Tim Garnett M.D, has served as an independent Director at Carmot Therapeutics since 2022. Prior to serving on the Carmot Board, Dr Garnett spent over 20 years at Eli Lilly in roles of increasing responsibility including serving as Chief Medical Officer from 2008 until 2021. At Lilly he led successful development of therapeutics in women’s health care, endocrinology and neuroscience through regulatory approval and successful launch in multiple geographies including the US, Europe, China and Japan. Dr Garnett has extensive experience leading clinical development, portfolio management, medical, regulatory and safety functions as well as a strategic understanding of the landscape for metabolic therapeutics.

Dr Garnett is a Board Member of Ophirex and a member of the Advisory Panel of Cambridge Innovation Capital. He holds a Bachelor of Medicine, Bachelor of Surgery (MBBS), is a Fellow of the Faculty of Pharmaceutical Medicine (FFPM), and a Fellow of the Royal College of Obstetricians and Gynaecologists (FRCOG).

Stig Hansen has served as Chief Executive Officer of Kimia Therapeutics, a spin-off of Carmot Therapeutics, since January 2023. Dr. Hansen co-founded Carmot Therapeutics and served as CEO from Carmot’s inception in 2008 through Kimia’s formation in January 2023. Dr. Hansen is the inventor of Chemotype Evolution, and he founded Carmot with a vision to transform drug discovery by industrializing Chemotype Evolution and applying it to high impact therapeutic targets. Under Dr. Hansen’s leadership, Carmot advanced the Chemotype Evolution platform as well as the development of a pipeline comprising preclinical and clinical novel dual incretin modulators for the treatment of metabolic diseases and oncology. Prior to Carmot, Dr. Hansen was director of biology at Sunesis Pharmaceuticals, where he invented Chemotype Evolution and led drug discovery programs in metabolic disease, auto-immunity, and oncology, advancing two programs into clinical development. Dr. Hansen holds an MS in biochemistry and a PhD in molecular and cell biology from the University of Copenhagen, Denmark. He conducted his Ph.D. studies in the laboratory of Dr. Robert Tjian at UC Berkeley, where he went on to become a Novartis Fellow of the Life Sciences Research Foundation studying mammalian brain development as a post-doctoral fellow.

Tim Kutzkey is a Managing Partner of The Column Group. Since joining the firm in 2007 he has contributed to the conception, formation, and management of more than a dozen portfolio companies. He currently serves as the Chairman of the Board of Directors of Neurona Therapeutics, Surrozen, and Nura Bio, all companies for which he had served previously as the founding CEO. In addition, Dr. Kutzkey is a member of the Board of Directors of Kallyope, Plexium, Cajal Neuroscience, Synthekine, Carmot, and Atavistik Bio. Formerly, he was the founding CEO of Peloton Therapeutics and the Chairman of the Board of Directors of Nurix Therapeutics. Prior to joining The Column Group, Dr. Kutzkey was a scientist at KAI Pharmaceuticals where he focused on the discovery and development of selective protein kinase C inhibitors. Before KAI, he worked at UC Berkeley as a graduate student and postdoc in the lab of Dr. Robert Tjian, completing his Ph.D. in 2005. Dr. Kutzkey was previously educated at Stanford University.

Anne Phillips, MD has served as an Independent Director at Carmot since 2022. Prior to joining Carmot, Dr Phillips was Senior Vice President, Clinical Development, Medical & Regulatory Affairs for Novo Nordisk Inc. since March 2013. At Novo, she led an integrated team across drug development, clinical operations, medical, regulatory, health economics and outcomes research, and pharmacovigilance. Dr. Phillips played a key role in advancing Novo Nordisk’s diabetes, obesity and biopharmaceuticals clinical development pipelines and was responsible for the efficient development and delivery of compounds in clinical trials, including product lifecycle and in-licensed compounds.

Before joining Novo Nordisk in 2011, Dr. Phillips was Vice President of Clinical Development at GlaxoSmithKline (GSK), leading diverse global and regional clinical teams supporting cardiovascular, metabolic, and oncology medicines, as well as drug discovery and Biotech alliance creation and execution. While at GSK, she provided clinical leadership and partnership in the management of one of the company’s largest medicines and formulated a deep level of understanding of the needs of both patients and healthcare professionals.

Dr. Phillips has worked in the Pharmaceutical Industry on programs in cardiovascular, metabolic, oncology/hematology, and in roles including drug discovery, business development, safety and pharmaco-vigilence and as leader of Clinical Development, Medical and Regulatory Affairs (CMR) as well as Head of R&D.

Previously, Dr Phillips was Head of the Infectious Diseases Program and Deputy Physician-in-Chief at Wellesley Central Hospital/St. Michael’s Hospital in Toronto and is a Fellow of The Royal College of Physicians and Surgeons of Canada.

Peter Svennilson is a Founder and Managing Partner of The Column Group (TCG) and has worked in venture capital and finance for 35 years. He was the Chairman of Aragon Pharmaceuticals from startup until it was sold to Johnson & Johnson in 2013 and Seragon Pharmaceuticals until it was sold to Genentech/Roche in 2014 and was a board director of NGM Biopharmaceuticals (“NGM” on NASDAQ) and Constellation Pharmaceuticals (“CNST” on NASDAQ). Mr. Svennilson is currently a board director of Revolution Medicines (“RVMD” on NASDAQ), ORIC Pharmaceuticals (“ORIC” on NASDAQ), RAPT Therapeutics (“RAPT” on NASDAQ), Ribon Therapeutics, Carmot Therapeutics and Circle Pharma. Prior to TCG, he was the Founder and Managing Partner of Three Crowns Capital where he helped finance large parts of the venture capital for biotech companies such as Tularik, Rosetta, PTC, Chemocentryx, Rinat, Tercica, Somalogic, Infinity and Five Prime. Prior to Three Crowns Capital, he was the Associate Managing Director in charge of European investment banking origination at Nomura in London. Mr. Svennilson is a Trustee at The Institute for Advanced Study in Princeton, New Jersey. Mr. Svennilson received an M.B.A. from the Stockholm School of Economics and Finance.

Aetna Wun Trombley has served as an independent director of Carmot Therapeutics since 2016. She is currently the President and CEO and a director at Lycia Therapeutics, a private biotech company focused on discovering and developing potential first-in-class therapeutics that degrade extracellular proteins. Prior to joining Lycia, Dr. Trombley was President and Chief Operating Officer of NGM Biopharmaceuticals (NASDAQ: NGM), where she had broad strategic and operational responsibilities for nine years. At NGM, she was instrumental in establishing multiple strategic partnerships and a successful initial public offering in 2019. Previously, she served as Chief of Staff for the Chief Executive Officer of Novartis and worked at XenoPort (NASDAQ: XNPT) in business development. She started her career at McKinsey & Company, where she advised biopharmaceutical and medical device clients on strategic, commercial and operational issues. She received a B.S. in Chemistry from the University of California, San Diego and a Ph.D. in Chemistry from MIT.

Heather Turner has served as Chief Executive Officer since January 2023. Ms. Turner brings over 20 years of leadership experience in life science companies including senior operational roles and legal expertise. Heather joined Carmot as Chief Operating Officer in 2022 and was responsible for Carmot’s operations and governance. In this role, Ms. Turner led the G&A functions as well as portfolio management. Prior to Carmot, Ms. Turner served as Chief General Counsel and Secretary at Lyell Immunopharma, Inc. serving as a member of the executive team and overseeing the legal organization. During her tenure she led and oversaw the finance, investor relations and alliance management functions. Notably, she oversaw the execution of the company’s $400 million Series C financing and the company’s IPO which raised gross proceeds of approximately $425 million, Nasdaq’s fourth largest biotech IPO. In addition, Ms. Turner significantly engaged in numerous strategic partnerships including the Company’s development and commercialization partnership with GSK which included a $200 million investment. Prior to Lyell, Ms. Turner served as Executive Vice President, General Counsel and Secretary of Sangamo Therapeutics, Inc. a publicly traded gene therapy and gene editing company, where she oversaw the legal and human resources organizations and led the company’s acquisition and integration of a publicly traded French company as well as its expansion into Europe. Prior to Sangamo, Ms. Turner served as Executive Vice President, General Counsel and Head of Portfolio Strategy at Atara Biotherapeutics, Inc., a publicly-traded allogeneic cell therapy company, where she oversaw legal, portfolio strategy, human resources and medical affairs. She also led secondary financings as well as international tax planning and implementation. Prior to Atara, Ms. Turner served as General Counsel and Secretary at Orexigen Therapeutics, Inc. a publicly-traded company focused on metabolic diseases. During her tenure at Orexigen, Ms. Turner oversaw the legal, human resources, government affairs and facilities functions. Ms. Turner was also actively involved in engagements with FDA and EMA related to their approvals of Orexigen’s obesity drug. Ms. Turner started her career at Cooley as a corporate securities associate. Ms. Turner received her J.D. from UCLA School of Law and her B.A. in Environmental Studies from the University of California, Santa Barbara.